46 results on '"Wæhre, Håkon"'
Search Results
2. Data from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
3. Supplementary Table 1 from STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
4. Supplementary Figure 5 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
5. Data from STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
6. Supplementary Figure 7 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
7. Supplementary Figure Legends 1-7 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
8. Supplementary Figure 3 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
9. Supplementary Figure 6 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
10. Supplementary Figure 1 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
11. PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer
12. Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
13. Divergent androgen regulation of unfolded protein response pathways drives prostate cancer
14. STAMP2 increases oxidative stress and is critical for prostate cancer
15. Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer
16. Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses
17. Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy
18. Brachytherapy for Prostate Cancer: A Systematic Review of Clinical and Cost Effectiveness
19. Chromatin organisation and cancer prognosis: a pan-cancer study
20. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy
21. Tumour heterogeneity poses a significant challenge to cancer biomarker research.
22. Chromatin changes predict recurrence after radical prostatectomy.
23. Correction: TCTP Is an Androgen-Regulated Gene Implicated in Prostate Cancer
24. Fifteen-year mortality after radical prostatectomy: Which factors are available for patient counselling?
25. TCTP Is an Androgen-Regulated Gene Implicated in Prostate Cancer
26. TCTP is Androgen‐Regulated and Over‐Expressed in Prostate Cancer
27. STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
28. Large Scale Genomic Instability as an Additive Prognostic Marker in Early Prostate Cancer
29. The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
30. Kallikrein 4 Is a Proliferative Factor that Is Overexpressed in Prostate Cancer
31. Sentinel node procedure in low-stage/low-grade penile carcinomas
32. Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making
33. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
34. Total Pelvic Exenteration with Preoperative Irradiation for Advanced Primary and Recurrent Rectal Cancer
35. Fifteen-year mortality after radical prostatectomy: Which factors are available for patient counselling?
36. Influence of Urological Morbidity on Quality of Life in Patients with Prostate Cancer
37. DNA ploidy in cell nuclei from paraffin-embedded material-comparison of results from two laboratories
38. Large scale genomic instability as an additive prognostic marker in early prostate cancer.
39. DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I
40. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer.
41. High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy.
42. Progression in Untreated Carcinoma of the Prostate Metastatic to Regional Lymph Nodes (Stage T0 to 4,N1 to 3,M0,D1)
43. Large Scale Genomic Instability as an Additive Prognostic Marker in Early Prostate Cancer
44. Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer.
45. [Treatment of hormone-resistant prostate cancer].
46. [Brachytherapy in prostatic cancer].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.